MedTrace Logo

Luspatercept in Patients Affected With Rare Inherited Anemias

NCT07331818 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-01-12

No results posted yet for this study

Summary

This is a prospective multicenter phase II basket trial evaluating Luspatercept in patients affected with rare inherited anemias

Conditions

  • Hereditary Red Blood Cell Disorder (Disorder)

Interventions

DRUG

Reblozyl

Reblozyl 25 mg powder for solution for injection / Reblozyl 75 mg powder for solution for injection

Sponsors & Collaborators

  • EuroBloodNet Association

    lead OTHER

Principal Investigators

  • Thierry Leblanc, Phd · Assistance Publique Hôpitaux de Paris - Hôpital Robert-Debré

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2028-09-30
Completion
2029-09-30

Countries

  • France
  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07331818 on ClinicalTrials.gov